Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement.
Authors:
B. Whitcomb, C. Lutman, M. Pearl, E. Medlin, E. Prendergast, K. Robison, W. Burke
Published in Gynecologic Oncology
10 January 2020
Highlights
• Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) affect the human endocannabinoid system.
• Cannabinoids reduce chemotherapy induced nausea or vomiting (CINV) and neuropathic pain.
• Each state has its own regulations for medical and recreational cannabis use.
• Effects of cannabinoids on chemotherapy, immunotherapy, and tumor growth remain under investigation.
• Providers should focus indications, alternatives, risks and benefits of medical cannabis use to make appropriate referrals.
DOI: 10.1016/j.ygyno.2019.12.013
PAYWALL
Citation:
Whitcomb B, Lutman C, Pearl M, et al. Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement. Gynecol Oncol. January 2020. doi:10.1016/j.ygyno.2019.12.013
